ArticleJournal of obstetrics and gynaecology of India2025
Case Report on Dedifferentiated Carcinoma of Endometrium and It's Histopathological Characteristics.
Article in Journal of obstetrics and gynaecology of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The DEAC, a rare entity, has an unfavorable clinical outcome. The role of adjuvant therapy is also controversial in this high-risk variety. The current FIGO grading may also lead to misdiagnosis of DEAC as FIGO grade 2 or 3 endometroid carcinoma, owing to histological insufficiency in assessing the details of solid component within a tumor. The recognition of UC component as a solid patternless growth is extremely important for a correct diagnosis of DEAC. Hereby, a 51-year-old female is presented with chief complaint of postmenopausal bleeding, with D&C report of a poorly differentiated carcinoma of endometrium. Complete comprehensive surgical staging was performed. The final HPE revealed 85-90% UC and 10-15% moderately differentiated endometroid carcinoma, which was finally IHC-proven as well. The disease was found metastatic to adnexa and retroperitoneal lymph nodes. Postoperatively patient was given chemotherapy as adjuvant therapy and she is asymptomatic on follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.